<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background- Previous observational studies demonstrated that patients with <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> at risk for <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> (SCD) may benefit from implantable cardioverter defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>A complete overview of outcome and complications after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy is currently not available </plain></SENT>
<SENT sid="2" pm="."><plain>This study pools data from published studies on outcome and complications after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in patients with <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Methods and Results- A PubMed database search returned 27 studies on 16 cohorts reporting outcome and complications after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in patients with <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In case of &gt;1 publications on a particular cohort, the publication with the largest number of patients was included in the meta-analysis </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> interventions, complications, and mortality rates were extracted, pooled, and analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>There were 2190 patients (mean age, 42 years; 38% women), most of whom (83%) received an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> for primary prevention of SCD </plain></SENT>
<SENT sid="7" pm="."><plain>Risk factors for SCD were left ventricular wall thickness â‰¥30 mm (20%), family history of SCD (43%), nonsustained <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (46%), <z:hpo ids='HP_0001279'>syncope</z:hpo> (41%), and abnormal blood pressure response (25%) </plain></SENT>
<SENT sid="8" pm="."><plain>During the 3.7-year follow-up, the annualized cardiac mortality rate was 0.6%, the noncardiac mortality rate was 0.4%, and the appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> intervention rate was 3.3% </plain></SENT>
<SENT sid="9" pm="."><plain>The annualized inappropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> intervention rate was 4.8% and the annualized <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-related complication rate was 3.4% </plain></SENT>
<SENT sid="10" pm="."><plain>Conclusions- This meta-analysis demonstrates a low cardiac and noncardiac mortality rate after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in patients with <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> intervention occurred at a rate of 3.3%/year, thereby, most probably, preventing SCD </plain></SENT>
<SENT sid="12" pm="."><plain>Inappropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> intervention and complications are not uncommon </plain></SENT>
</text></document>